Small Cap GOAT

Clean small-cap setups, research and ideas. Education only. Not financial advice.

[Small Cap GOAT @smallcapgoat]

$JUNS bull case in 4 tweets:

• Phase 2a RESET Parkinson’s trial now enrolling patients
• JOTROL designed to solve the bioavailability issues that have historically limited resveratrol
• Focus on neuroinflammation, oxidative stress and mitochondrial dysfunction pathways

[Small Cap GOAT @smallcapgoat]

@stockplaymaker1 $JUNS

[Small Cap GOAT @smallcapgoat]

For $JUNS asking about the $100M deal easy to find PR but this is the video from Emerging Growth

Have a nice weekend!

[Small Cap GOAT @smallcapgoat]

$JUNS must watch from today’s conference! Future is bright

https://t.co/yO8fCMfEs2

[Small Cap GOAT @smallcapgoat]

@PPortfolioooo You too P

[Small Cap GOAT @smallcapgoat]

@PPortfolioooo Yep they are targeting an acquisition by big pharma company is what it sounds like

[Small Cap GOAT @smallcapgoat]

$JUNS was getting loaded down here and looks ready to pop

Really nice daily bullish divergence on one of my fav indicators this has a high hit rate

[Small Cap GOAT @smallcapgoat]

@stockplaymaker1 @TopStockAlerts1 @TT_stocks_ @SarwanJohn @MarkBagger @HunterAllen4 @greatstockpicks soooo thin 1.5M float

[Small Cap GOAT @smallcapgoat]

$AERT should be 1.56M float after the split tomorrow

They did it to regain compliance. Many bullish developments recently

@ZacksResearch called it a hidden gem and gave it an Outperform rating

$70M revenue $3.5M net income

[SheepWolf 💫 @realsheepwolf]

$AERT we like getting them before the market realizes
•Float=12M
•No active overhang
•$5.0 million share repurchase program

THIS IS HOW $RUBI STARTED AT 0.50

CLEAN PLAYS RUN BETTER MY FRIENDS

$PPCB $RUBI $GELS $ONEG $GLXG $CCHH $QH

[Small Cap GOAT @smallcapgoat]

$JUNS must watch from today’s conference! Future is bright

https://t.co/yO8fCMfEs2

[Small Cap GOAT @smallcapgoat]

Out of both btw

[Small Cap GOAT @smallcapgoat]

Gave you $CHOW and $CCHH

[Small Cap GOAT @smallcapgoat]

@stockplaymaker1 $CCHH Malaysia did 100% in AH the other day wants a big move. On theme 👀

[Small Cap GOAT @smallcapgoat]

@stockplaymaker1 $CCHH Malaysia did 100% in AH the other day wants a big move. On theme 👀

[Small Cap GOAT @smallcapgoat]

$JUNS loaded the rest of my position from the impatient

Undervalued down here IMO

[B2i Digital @b2idigital]

Jupiter Neurosciences (NASDAQ: JUNS) (@jupiterneuro) (@Nasdaq) , a B2i Digital (@b2idigital) Featured Company, presents a live corporate update at the Emerging Growth Conference on June 10, 2026 at 2:20 PM ET, with a short Q&A to follow.

Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.

Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://t.co/6WrszZEjkN

The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:

• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from PharmAla Biotech (@PharmAlaBiotech), putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• Nugevia, its revenue-generating consumer longevity line, available now at https://t.co/O5zrS51M3M

Register to attend:
https://t.co/p6ggR1lsZp

Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://t.co/xFQPqngoxB.

Disclosure: David Shapiro (@davidshapiroNYC), CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://t.co/ljTVqQKx2K.

[Small Cap GOAT @smallcapgoat]

Not just a marketing partner @davidshapiroNYC has purchased $JUNS on open market 🐂

@PPortfolioooo @SarwanJohn @greatstockpicks

[B2i Digital @b2idigital]

Jupiter Neurosciences (NASDAQ: JUNS) (@jupiterneuro) (@Nasdaq) , a B2i Digital (@b2idigital) Featured Company, presents a live corporate update at the Emerging Growth Conference on June 10, 2026 at 2:20 PM ET, with a short Q&A to follow.

Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.

Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://t.co/6WrszZEjkN

The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:

• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from PharmAla Biotech (@PharmAlaBiotech), putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• Nugevia, its revenue-generating consumer longevity line, available now at https://t.co/O5zrS51M3M

Register to attend:
https://t.co/p6ggR1lsZp

Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://t.co/xFQPqngoxB.

Disclosure: David Shapiro (@davidshapiroNYC), CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://t.co/ljTVqQKx2K.

[Small Cap GOAT @smallcapgoat]

@PPortfolioooo Low volume people hopping out to chase Chinese P&D will regret later

[Small Cap GOAT @smallcapgoat]

$JUNS

[Small Cap GOAT @smallcapgoat]

$JUNS

[B2i Digital @b2idigital]

Jupiter Neurosciences (NASDAQ: JUNS) (@jupiterneuro) (@Nasdaq) , a B2i Digital (@b2idigital) Featured Company, presents a live corporate update at the Emerging Growth Conference on June 10, 2026 at 2:20 PM ET, with a short Q&A to follow.

Jupiter is a clinical-stage biopharmaceutical company focused on the central nervous system and neuroinflammation, with a second path into the fast-growing consumer longevity market.

Jupiter Neurosciences is a B2i Digital Featured Company. See the company's profile at https://t.co/6WrszZEjkN

The update caps one of the busiest runs in the company's history. A few things management is expected to walk through:

• A $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic licensed from PharmAla Biotech (@PharmAlaBiotech), putting JUNS at the front of the U.S. psychedelic medicine space following the April 18 federal Executive Order opening access to investigational psychedelic therapies
• JOTROL, its lead program, an enhanced bioavailability resveratrol formulation now in a Phase IIa clinical trial for Parkinson's disease
• Nugevia, its revenue-generating consumer longevity line, available now at https://t.co/O5zrS51M3M

Register to attend:
https://t.co/p6ggR1lsZp

Jupiter Neurosciences is a clinical-stage biopharmaceutical company advancing JOTROL, a proprietary enhanced bioavailability resveratrol formulation, with a Phase IIa Parkinson's disease trial underway and a consumer longevity line, Nugevia. It trades on Nasdaq under JUNS.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://t.co/xFQPqngoxB.

Disclosure: David Shapiro (@davidshapiroNYC), CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is informational only and is not an offer, solicitation, or recommendation regarding any security, and it does not offer any opinion on JUNS as an investment. Conduct your own research and consult your own professional advisors before making any investment decision. B2i Digital is not a broker-dealer or investment adviser. See the complete Disclosure at https://t.co/ljTVqQKx2K.

[Small Cap GOAT @smallcapgoat]

$JUNS

[ABC News @ABC]

A new study of more than 111,000 women ages 45 to 80 found those on GLP-1 medications had a reduced risk of developing breast cancer by about 30%. https://t.co/d88z6D6YBQ

[Small Cap GOAT @smallcapgoat]

@SarwanJohn Stock options not insider buy but still good they need to execute and increase share price in the mid term to maximize value of them. COO/President has a pretty impressive resume!

[Small Cap GOAT @smallcapgoat]

@NickPappagiorg @moonmarket @PPortfolioooo Check out pinned tweet and below https://t.co/ac6NMu3ET7